BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism Jul 13, 2026 08:00AM
BetterLife Pharma adds legal veteran to board, reports warrant proceeds Jul 9, 2026 08:02AM
BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee Jul 9, 2026 08:00AM
BetterLife Pharma hires Nucro-Technics for final BETR-001 toxicology study Jul 6, 2026 08:02AM
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1 Jul 6, 2026 08:00AM


Jun 25, 2026 08:02AM BetterLife Pharma hires Syner-G for GMP manufacturing of BETR-001
Jun 25, 2026 08:00AM BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
Jun 22, 2026 08:00AM BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
May 13, 2026 08:05AM BetterLife Pharma names Doug Drysdale as Executive Chairman
May 13, 2026 08:00AM BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
Jan 6, 2026 08:00AM BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco
Dec 11, 2025 08:00AM BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital